Sponsors (35)
The bill tightens federal safety controls and monitoring for medication abortion but does so by restricting access, raising costs and travel burdens, increasing provider and manufacturer compliance obligations, and creating privacy/legal risks that could reduce availability and innovation.
Women seeking medication abortion and the clinicians who provide it would face stricter safety controls — requiring in-person administration and practitioner certification — which may reduce risks from unsupervised at‑home use.
Manufacturers and clinicians would be required to report serious adverse events (without identifiable patient information), improving FDA visibility into safety problems and monitoring of medication safety.
The bill establishes a clear federal gestational-age boundary (no use after 70 days) and limits on label changes, creating a more definite safety cutoff for providers and patients.
Women would have substantially reduced access to medication abortion because the bill bars new approvals and investigational trials and requires in‑person clinic/hospital administration rather than pharmacy or telehealth.
Mandatory reporting of drug administration 'as required by State law' or classifying administration as surgical abortion increases privacy and legal risks for patients in states with restrictive laws, potentially exposing them to prosecution or immigration consequences.
Patients — especially low‑income and rural individuals — are likely to face higher out‑of‑pocket costs and travel burdens because drugs must be administered in clinics or hospitals instead of via pharmacy pickup or telehealth.
Based on analysis of 2 sections of legislative text.
Bars new FDA approvals and many trials for abortion drugs; limits approved drugs to in-person administration within 70 days’ gestation and imposes REMS, certification, and reporting requirements.
Official title: Amend the Federal Food, Drug, and Cosmetic Act to prohibit the approval of new abortion drugs, to prohibit investigational use exemptions for abortion drugs, and to impose additional regulatory requirements with respect to previously approved abortion drugs, and for other purposes.
Introduced January 27, 2026 by Cindy Hyde-Smith · Last progress January 27, 2026
Prohibits FDA approval or investigational use exemptions for new “abortion drugs,” and places strict limits and safety requirements on any abortion drugs already approved when the law takes effect. For existing drugs, it bars label changes that allow use after 70 days’ gestation, requires in-person administration by the prescribing practitioner, treats them under more restrictive compounding/dispensing rules, and mandates a REMS with practitioner certification, reporting, and dispensing controls; certain ongoing investigational studies would be terminated within three years if they would be prohibited. The law adds definitions for key terms (including “abortion drug,” “gestation,” and “unborn child”), creates new adverse-event reporting duties for manufacturers and clinicians (with patient identity protections), and gives FDA authority to impose and enforce the listed safety, certification, and reporting requirements on manufacturers and health care practitioners.